NO332190B1 - Enterisk belagt pyridoksin HCl- og doksylaminsuksinat-preparat med rask virkningsinntreden, anvendelse derav, medikament og fremgangsmate for fremstilling av preparatet. - Google Patents

Enterisk belagt pyridoksin HCl- og doksylaminsuksinat-preparat med rask virkningsinntreden, anvendelse derav, medikament og fremgangsmate for fremstilling av preparatet. Download PDF

Info

Publication number: NO332190B1
Authority: NO; Norway
Prior art keywords: approx; preparation; doxylamine succinate; rapid onset; weight
Prior art date: 2000-12-20

Application number

NO20022982A

Other languages

English (en)

Norwegian (no)

Other versions

NO20022982D0 (no

NO20022982L (no

Inventor

Eric Cervais

Original Assignee

Duchesnay Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-20

Filing date

2002-06-20

Publication date

2012-07-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42104724&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO332190(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-06-20 Application filed by Duchesnay Inc filed Critical Duchesnay Inc

2002-06-20 Publication of NO20022982D0 publication Critical patent/NO20022982D0/no

2002-10-09 Publication of NO20022982L publication Critical patent/NO20022982L/no

2012-07-23 Publication of NO332190B1 publication Critical patent/NO332190B1/no

Links

238000002360 preparation method Methods 0.000 title claims abstract description 71
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 title claims abstract description 64
229940011671 vitamin b6 Drugs 0.000 title claims abstract description 43
KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 title claims abstract description 37
229960005008 doxylamine succinate Drugs 0.000 title claims abstract description 37
235000019171 pyridoxine hydrochloride Nutrition 0.000 title claims abstract description 22
239000011764 pyridoxine hydrochloride Substances 0.000 title claims abstract description 22
239000003814 drug Substances 0.000 title claims description 13
229940079593 drug Drugs 0.000 title claims description 7
238000000034 method Methods 0.000 title claims description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 35
238000004090 dissolution Methods 0.000 claims abstract description 34
238000005259 measurement Methods 0.000 claims abstract description 21
239000000203 mixture Substances 0.000 claims abstract description 20
239000002702 enteric coating Substances 0.000 claims abstract description 17
238000009505 enteric coating Methods 0.000 claims abstract description 17
239000000377 silicon dioxide Substances 0.000 claims abstract description 16
239000008363 phosphate buffer Substances 0.000 claims abstract description 10
239000011230 binding agent Substances 0.000 claims abstract description 8
239000000945 filler Substances 0.000 claims abstract description 8
239000003381 stabilizer Substances 0.000 claims abstract description 8
239000000654 additive Substances 0.000 claims abstract description 7
239000003795 chemical substances by application Substances 0.000 claims abstract description 6
235000008160 pyridoxine Nutrition 0.000 claims description 21
239000011677 pyridoxine Substances 0.000 claims description 21
239000004480 active ingredient Substances 0.000 claims description 20
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
238000000576 coating method Methods 0.000 claims description 14
239000011248 coating agent Substances 0.000 claims description 13
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
206010047700 Vomiting Diseases 0.000 claims description 10
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
239000008108 microcrystalline cellulose Substances 0.000 claims description 10
229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 8
239000000391 magnesium silicate Substances 0.000 claims description 8
235000019359 magnesium stearate Nutrition 0.000 claims description 8
229940099273 magnesium trisilicate Drugs 0.000 claims description 8
235000019793 magnesium trisilicate Nutrition 0.000 claims description 8
229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 8
208000024891 symptom Diseases 0.000 claims description 8
229920002785 Croscarmellose sodium Polymers 0.000 claims description 7
229960001681 croscarmellose sodium Drugs 0.000 claims description 7
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 7
239000010687 lubricating oil Substances 0.000 claims description 7
239000003607 modifier Substances 0.000 claims description 7
235000012239 silicon dioxide Nutrition 0.000 claims description 7
239000007884 disintegrant Substances 0.000 claims description 5
238000007789 sealing Methods 0.000 claims description 5
230000035935 pregnancy Effects 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 2
238000009500 colour coating Methods 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
230000003313 weakening effect Effects 0.000 claims 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 1
239000000314 lubricant Substances 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1
239000003826 tablet Substances 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 7
AAYNMUXDBOPKCP-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;butanedioic acid;n,n-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine;hydron;chloride Chemical compound Cl.OC(=O)CCC(O)=O.CC1=NC=C(CO)C(CO)=C1O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 AAYNMUXDBOPKCP-UHFFFAOYSA-N 0.000 description 6
229960005178 doxylamine Drugs 0.000 description 6
HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 6
229920002472 Starch Polymers 0.000 description 5
239000012530 fluid Substances 0.000 description 5
229940032147 starch Drugs 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000008107 starch Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
229960001866 silicon dioxide Drugs 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229940072056 alginate Drugs 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
229940105329 carboxymethylcellulose Drugs 0.000 description 3
229940075614 colloidal silicon dioxide Drugs 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
229940071676 hydroxypropylcellulose Drugs 0.000 description 3
235000010413 sodium alginate Nutrition 0.000 description 3
239000000661 sodium alginate Substances 0.000 description 3
229940005550 sodium alginate Drugs 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920002907 Guar gum Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
235000012216 bentonite Nutrition 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000002662 enteric coated tablet Substances 0.000 description 2
235000010417 guar gum Nutrition 0.000 description 2
239000000665 guar gum Substances 0.000 description 2
229960002154 guar gum Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000008693 nausea Effects 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
229940068984 polyvinyl alcohol Drugs 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
230000035943 smell Effects 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
235000019640 taste Nutrition 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
RHSGKJLQXVZBMZ-UHFFFAOYSA-N C(C)(=O)ON(CN(OC(C)=O)OC(C)=O)OC(C)=O.[Na].[Na] Chemical compound C(C)(=O)ON(CN(OC(C)=O)OC(C)=O)OC(C)=O.[Na].[Na] RHSGKJLQXVZBMZ-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
201000010538 Lactose Intolerance Diseases 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
229940050528 albumin Drugs 0.000 description 1
229940092782 bentonite Drugs 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
235000010338 boric acid Nutrition 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000019519 canola oil Nutrition 0.000 description 1
239000000828 canola oil Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
229940082483 carnauba wax Drugs 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
-1 dextrates Chemical compound 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000005498 phthalate group Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
235000007686 potassium Nutrition 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
239000000770 propane-1,2-diol alginate Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Otolaryngology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hospice & Palliative Care (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Lubricants (AREA)
Seal Device For Vehicle (AREA)
Memory System Of A Hierarchy Structure (AREA)
Power Steering Mechanism (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20022982A 2000-12-20 2002-06-20 Enterisk belagt pyridoksin HCl- og doksylaminsuksinat-preparat med rask virkningsinntreden, anvendelse derav, medikament og fremgangsmate for fremstilling av preparatet. NO332190B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CA002350195A CA2350195C (fr)	2000-12-20	2000-12-20	Preparation a delai d'action rapide de chlorhydrate de pyridoxine et de doxylamine succinate
PCT/CA2001/000951 WO2003000263A1 (fr)	2000-12-20	2001-06-21	Forme galenique a court delai d'action
US09/885,051 US6340695B1 (en)	2000-12-20	2001-06-21	Rapid onset formulation

Publications (3)

Publication Number	Publication Date
NO20022982D0 NO20022982D0 (no)	2002-06-20
NO20022982L NO20022982L (no)	2002-10-09
NO332190B1 true NO332190B1 (no)	2012-07-23

Family

ID=42104724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022982A NO332190B1 (no)	2000-12-20	2002-06-20	Enterisk belagt pyridoksin HCl- og doksylaminsuksinat-preparat med rask virkningsinntreden, anvendelse derav, medikament og fremgangsmate for fremstilling av preparatet.

Country Status (35)

Country	Link
US (1)	US6340695B1 (fr)
EP (1)	EP1397133B1 (fr)
JP (1)	JP4242763B2 (fr)
KR (1)	KR100527985B1 (fr)
CN (1)	CN1229112C (fr)
AT (1)	ATE307582T1 (fr)
AU (1)	AU2001272243B2 (fr)
BE (1)	BE1014929A4 (fr)
BR (1)	BR0107371A (fr)
CA (1)	CA2350195C (fr)
DE (2)	DE60114475T2 (fr)
DK (2)	DK1397133T3 (fr)
EG (1)	EG24483A (fr)
ES (1)	ES2251494T3 (fr)
FI (1)	FI117961B (fr)
FR (1)	FR2826277B1 (fr)
GB (1)	GB2383751C (fr)
GR (1)	GR1004371B (fr)
HK (1)	HK1052654A1 (fr)
HU (1)	HU227003B1 (fr)
IL (1)	IL150349A0 (fr)
IS (1)	IS2225B (fr)
IT (1)	ITTO20020524A1 (fr)
LU (1)	LU90934B1 (fr)
MC (1)	MC200059A1 (fr)
MX (1)	MXPA02006037A (fr)
MY (1)	MY132786A (fr)
NL (1)	NL1020895C2 (fr)
NO (1)	NO332190B1 (fr)
PL (1)	PL204507B1 (fr)
SE (1)	SE526307C2 (fr)
TR (1)	TR200201685T1 (fr)
UA (1)	UA74807C2 (fr)
UY (1)	UY27352A1 (fr)
WO (1)	WO2003000263A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2350195C (fr) *	2000-12-20	2003-06-10	Duchesnay Inc.	Preparation a delai d'action rapide de chlorhydrate de pyridoxine et de doxylamine succinate
US8257746B2 (en)	2001-04-10	2012-09-04	Pernix Therapeutics, Llc	Tannate compositions, methods of making and methods of use
US8012506B2 (en) *	2001-04-10	2011-09-06	Pernix Therapeutics, Llc	Tannate compositions, methods of making and methods of use
ES2229876B1 (es) *	2001-06-26	2006-03-01	Duchesnay Inc.	Formulacion de accion rapida.
CA2392486A1 (fr) *	2002-07-05	2002-12-08	Duchesnay Inc.	Forme posologique pharmaceutique portant une inscription pour les femmes enceintes
CA2406592C (fr) *	2002-10-04	2003-09-30	Duchesnay Inc.	Mode de preparation de formes posologiques pharmaceutiques contenant de multiples principes actifs
JP2004231520A (ja) *	2003-01-28	2004-08-19	Nichiko Pharmaceutical Co Ltd	保存安定性及び溶出速度に優れた医薬組成物
US20050004181A1 (en) *	2003-07-03	2005-01-06	Duchesnay Inc.	Use of anti-emetic for pre and post operative care
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
RU2401125C2 (ru)	2004-12-27	2010-10-10	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Способ стабилизации лекарственного средства против деменции
WO2006118265A1 (fr) *	2005-04-28	2006-11-09	Eisai R & D Management Co., Ltd.	Composition contenant un agent anti-démence
US20070277530A1 (en) *	2006-05-31	2007-12-06	Constantin Alexandru Dinu	Inlet flow conditioner for gas turbine engine fuel nozzle
CN102108059B (zh) *	2010-09-03	2012-05-09	合肥工业大学	一种琥珀酸多西拉敏的合成方法
US8950188B2 (en)	2011-09-09	2015-02-10	General Electric Company	Turning guide for combustion fuel nozzle in gas turbine and method to turn fuel flow entering combustion chamber
AU2013224598B2 (en) *	2012-02-22	2015-09-17	Duchesnay Inc.	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
WO2013123569A1 (fr) *	2012-02-22	2013-08-29	Duchesnay Inc.	Formulation à base de doxylamine et de pyridoxine et/ou de métabolites ou de sels associés
JP5818219B2 (ja)	2012-05-14	2015-11-18	塩野義製薬株式会社	６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
US9452181B2 (en)	2013-07-22	2016-09-27	Duchesnay Inc.	Composition for the management of nausea and vomiting
CN105492013B (zh)	2013-07-22	2018-09-18	达切斯内公司	用于管理恶心和呕吐的组合物
CN103432126A (zh) *	2013-08-05	2013-12-11	北京阜康仁生物制药科技有限公司	一种治疗孕吐的药物组合物
CN106794148B (zh) *	2014-08-29	2018-12-21	达切斯内公司	多西拉敏和吡哆醇和/或其代谢产物或盐的多模式释放制剂
TWI595874B (zh)	2014-08-29	2017-08-21	達契斯奈股份有限公司	多西拉敏及吡哆醇及／或其代謝產物或鹽之多模式釋放調配物
EP3337480A4 (fr)	2015-08-17	2019-05-08	Aequus Pharmaceuticals Inc.	Administration transdermique de succinate de doxylamine et de chlorhydrate de piridoxine
CN105510512B (zh) *	2016-01-25	2018-06-29	南京济群医药科技股份有限公司	一种琥珀酸多西拉敏有关物质的rt-hplc检测方法
PT3628311T (pt) *	2018-09-27	2021-02-09	Inibsa Ginecologia S A	Um processo para a preparação de uma forma de dosagem oral, de unidade múltipla de libertação modificada, de sucinato de doxilamina e cloridrato de piridoxina
CN114099450A (zh) *	2020-08-31	2022-03-01	长春海悦药业股份有限公司	一种比拉斯汀片及其制备方法
AU2021225255B1 (en) *	2021-09-03	2022-06-16	Patel, Mihir MR	Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2085641A1 (en) *	1970-04-20	1971-12-31	Investigations Sci Pharm	Noramidopyrine doxylamine succinate compsn - antiinflammatories analgesics and antipyretics
US4642231A (en) *	1983-07-20	1987-02-10	Warner-Lambert Company	Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines
CA2117351C (fr) *	1992-01-13	1998-03-03	Julian Belknap Lo	Methode de fabrication permettant d'accroitre la durete des comprimes
CA2139896C (fr) *	1995-01-10	2000-03-28	Don B. Mcdonah	Utilisation d'un agent antinauseeux chez des patients en phase terminale
US6013280A (en) *	1997-10-07	2000-01-11	Fuisz Technologies Ltd.	Immediate release dosage forms containing microspheres
JP2003509439A (ja) *	1999-09-14	2003-03-11	スミスクライン・ビーチャム・コーポレイション	水性コーティングされたビーズレットの製法
CA2350195C (fr) *	2000-12-20	2003-06-10	Duchesnay Inc.	Preparation a delai d'action rapide de chlorhydrate de pyridoxine et de doxylamine succinate

2000
- 2000-12-20 CA CA002350195A patent/CA2350195C/fr not_active Expired - Lifetime
2001
- 2001-06-21 WO PCT/CA2001/000951 patent/WO2003000263A1/fr active IP Right Grant
- 2001-06-21 ES ES01951259T patent/ES2251494T3/es not_active Expired - Lifetime
- 2001-06-21 EP EP01951259A patent/EP1397133B1/fr not_active Expired - Lifetime
- 2001-06-21 DK DK01951259T patent/DK1397133T3/da active
- 2001-06-21 DE DE60114475T patent/DE60114475T2/de not_active Expired - Lifetime
- 2001-06-21 MX MXPA02006037A patent/MXPA02006037A/es active IP Right Grant
- 2001-06-21 BR BR0107371-0A patent/BR0107371A/pt not_active Application Discontinuation
- 2001-06-21 IL IL15034901A patent/IL150349A0/xx active IP Right Grant
- 2001-06-21 UA UA2002065093A patent/UA74807C2/uk unknown
- 2001-06-21 AT AT01951259T patent/ATE307582T1/de active
- 2001-06-21 CN CNB018145485A patent/CN1229112C/zh not_active Expired - Fee Related
- 2001-06-21 KR KR10-2002-7009679A patent/KR100527985B1/ko active IP Right Review Request
- 2001-06-21 GB GB0213990A patent/GB2383751C/en not_active Expired - Lifetime
- 2001-06-21 JP JP2003506908A patent/JP4242763B2/ja not_active Expired - Fee Related
- 2001-06-21 AU AU2001272243A patent/AU2001272243B2/en not_active Expired
- 2001-06-21 DE DE10196426T patent/DE10196426T1/de not_active Ceased
- 2001-06-21 PL PL362763A patent/PL204507B1/pl unknown
- 2001-06-21 HU HU0301950A patent/HU227003B1/hu unknown
- 2001-06-21 TR TR2002/01685T patent/TR200201685T1/xx unknown
- 2001-06-21 US US09/885,051 patent/US6340695B1/en not_active Expired - Lifetime
2002
- 2002-06-07 IS IS6412A patent/IS2225B/is unknown
- 2002-06-12 GR GR20020100280A patent/GR1004371B/el unknown
- 2002-06-18 IT IT2002TO000524A patent/ITTO20020524A1/it unknown
- 2002-06-18 NL NL1020895A patent/NL1020895C2/nl not_active IP Right Cessation
- 2002-06-19 MY MYPI20022296A patent/MY132786A/en unknown
- 2002-06-19 EG EG2002060693A patent/EG24483A/xx active
- 2002-06-20 NO NO20022982A patent/NO332190B1/no not_active IP Right Cessation
- 2002-06-20 FR FR0207643A patent/FR2826277B1/fr not_active Expired - Lifetime
- 2002-06-20 MC MC2486A patent/MC200059A1/fr unknown
- 2002-06-20 DK DK200200947A patent/DK176018B1/da not_active IP Right Cessation
- 2002-06-20 BE BE2002/0397A patent/BE1014929A4/fr not_active IP Right Cessation
- 2002-06-21 LU LU90934A patent/LU90934B1/fr active
- 2002-06-21 UY UY27352A patent/UY27352A1/es not_active Application Discontinuation
- 2002-07-03 SE SE0202061A patent/SE526307C2/sv unknown
- 2002-09-25 FI FI20021708A patent/FI117961B/fi not_active IP Right Cessation
2003
- 2003-07-11 HK HK03105025A patent/HK1052654A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
PL204507B1 (pl)	2010-01-29
GB2383751A (en)	2003-07-09
GB2383751C (en)	2008-08-05
KR100527985B1 (ko)	2005-11-09
JP4242763B2 (ja)	2009-03-25
PL362763A1 (en)	2004-11-02
HUP0301950A2 (hu)	2003-11-28
GB0213990D0 (en)	2002-07-31
FI117961B (fi)	2007-05-15
DE10196426T1 (de)	2003-08-21
BE1014929A4 (fr)	2004-06-01
FI20021708A0 (fi)	2002-09-25
ES2251494T3 (es)	2006-05-01
GR1004371B (el)	2003-10-23
AU2001272243B2 (en)	2004-02-05
MC200059A1 (fr)	2003-01-30
HK1052654A1 (en)	2003-09-26
DK176018B1 (da)	2005-12-05
MXPA02006037A (es)	2005-05-12
EG24483A (en)	2009-08-09
SE526307C2 (sv)	2005-08-16
TR200201685T1 (tr)	2003-06-23
FR2826277B1 (fr)	2004-07-02
IL150349A0 (en)	2003-12-23
JP2004521146A (ja)	2004-07-15
BR0107371A (pt)	2003-06-10
DK200200947A (da)	2003-01-03
KR20030023612A (ko)	2003-03-19
WO2003000263A1 (fr)	2003-01-03
US6340695B1 (en)	2002-01-22
NL1020895A1 (nl)	2002-12-30
NO20022982D0 (no)	2002-06-20
DE60114475D1 (de)	2005-12-01
CN1447694A (zh)	2003-10-08
FI20021708A (fi)	2002-12-22
HU227003B1 (en)	2010-04-28
IS2225B (is)	2007-04-15
ATE307582T1 (de)	2005-11-15
CA2350195A1 (fr)	2001-08-11
IS6412A (is)	2002-12-22
EP1397133B1 (fr)	2005-10-26
ITTO20020524A1 (it)	2003-12-18
EP1397133A1 (fr)	2004-03-17
MY132786A (en)	2007-10-31
NO20022982L (no)	2002-10-09
CA2350195C (fr)	2003-06-10
SE0202061L (sv)	2003-01-28
LU90934B1 (fr)	2002-12-23
GR20020100280A (el)	2003-03-28
SE0202061D0 (sv)	2002-07-03
HUP0301950A3 (en)	2005-06-28
NL1020895C2 (nl)	2003-03-13
UY27352A1 (es)	2002-09-30
ITTO20020524A0 (it)	2002-06-18
GB2383751B (en)	2005-02-09
DE60114475T2 (de)	2006-07-13
CN1229112C (zh)	2005-11-30
DK1397133T3 (da)	2006-02-27
IE20020488A1 (en)	2003-04-30
FR2826277A1 (fr)	2002-12-27
UA74807C2 (en)	2006-02-15

Legal Events

Date	Code	Title	Description
2021-07-12	MK1K	Patent expired

Publication	Publication Date	Title
NO332190B1 (no)	2012-07-23	Enterisk belagt pyridoksin HCl- og doksylaminsuksinat-preparat med rask virkningsinntreden, anvendelse derav, medikament og fremgangsmate for fremstilling av preparatet.
AU2001272243A1 (en)	2003-06-19	Rapid onset formulation
RU2616516C2 (ru)	2017-04-17	Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль
AU2004275469B2 (en)	2010-07-15	HRT formulations
JP6051467B2 (ja)	2016-12-27	アロマターゼ阻害剤を含む医薬組成物
CN101686941A (zh)	2010-03-31	包含苯并氮杂的药物固体制剂及其生产方法
JP2007529564A5 (fr)	2008-05-08
NO329896B1 (no)	2011-01-24	Farmasoytisk sammensetning og anvendelse derav
EP4054537A1 (fr)	2022-09-14	Formulation orale de x842
JPWO2016175230A1 (ja)	2018-02-22	経口投与用医薬組成物
KR20160092956A (ko)	2016-08-05	라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제
CN112220765A (zh)	2021-01-15	一种含有辛伐他汀的口服制剂及其制备方法
EP2320874A1 (fr)	2011-05-18	Composition pharmaceutique solide contenant de l'exémestane
JP2021518422A (ja)	2021-08-02	レナリドミドを含む医薬組成物
WO2012050539A1 (fr)	2012-04-19	Composition pharmaceutique comprenant l'eplérenone
RU2266744C2 (ru)	2005-12-27	Композиция быстрого начала действия
CN102526063A (zh)	2012-07-04	一种含有氯沙坦钾和氢***的复方制剂及其制备方法
JP2007302688A (ja)	2007-11-22	速効性処方剤
NZ519709A (en)	2004-06-25	Rapid onset formulation comprising pyridoxine HCL and doxylamine succinate
ES2229876B1 (es)	2006-03-01	Formulacion de accion rapida.
IE83699B1 (en)	2004-12-01	Rapid onset formulation
ZA200300594B (en)	2004-02-19	Rapid onset formulation.